Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study

Abstract

Background: Radiation-induced sarcomas (RIS) tend to have aggressive behaviour and because of their rarity, the most appropriate management for these malignancies is uncertain. Objectives: Using the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database, a national sarcoma registry, we aimed to investigate prognostic factors and outcomes for RIS. Design: Retrospective study of RIS patients treated from 1996 to 2021 at three Canadian centres. Methods: RIS was defined as a sarcoma arising in a previously irradiated field following a 3+ year latency period, whose histology was distinct from the initially irradiated tumour. Clinicopathologic and treatment-related information was extracted from the CanSaRCC database. Overall survival (OS) was defined as the time from RIS diagnosis to death from any cause. Response rate (RR) to neoadjuvant chemotherapy (NACT) was based on physician assessment. Time-to-event analyses were estimated using the Kaplan–Meier method, with Cox regression for multivariate analysis. We considered a two-tailed p-value of <0.05 as statistically significant. Results: One hundred seven tumours met the criteria for RIS and were divided into three subgroups: breast angiosarcoma (BAS, n = 54), osteosarcoma (OST, n = 16), and other soft-tissue sarcomas (STS, n = 37). Patients were mostly female ( n = 85, 79%), treated initially for breast carcinomas ( n = 54, 50.5%), and diagnosed with high-grade tumours ( n = 61/71, 86%). None had evidence of synchronous metastasis. Patients with OST were younger (median age: 48 years, p < 0.001), and BAS had the shortest latency interval (8 versus 18 years for OST/STS, p < 0.001). Most patients underwent surgery, 76% ( n = 76/100) R0; 24% ( n = 26) received radiation therapy, mostly ( n = 15, 57.7%) neoadjuvant. Among those receiving chemotherapy, 30 (75%) underwent NACT; among patients with documented response assessment, the RR was 68% ( n = 17/25), being even higher in the BAS population (89.5%, n = 13/17). Median OS was 53 months (95% CI 34–101), with a 5-year OS of 47.6%; larger tumour size, high histologic grade and older age were independent prognostic factors for worse OS. Conclusion: Surgery is standard, and NACT might be useful to downsize large lesions, especially in BAS patients. Raising RIS awareness is fundamental to promoting appropriate management and fostering research through multi-institutional collaborations.

Bone Radiation-Induced Sarcomas: Outcomes Based on Histology and Surgical Treatment

“…was consulted and the final decision was reached by con-sensus. A total of 22 articles met our inclusion criteria and progressed to quality assessment [5][6][7][8][9]11,[13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] .…”

Outcomes of non‐angiosarcoma radiation‐associated soft tissue sarcomas of the chest

“…8,9 For patients who develop a RA-STS, treatment often includes surgical resection with consideration for chemotherapy and additional radiotherapy. [10][11][12] Since angiosarcoma is the most common RA-STS observed in the chest, 9,13 studies examining treatment outcomes have mainly focused on this specific histology or combine all histologies which makes it difficult to determine treatment outcomes for patients with these rare tumors. 13 As such, we sought to evaluate the outcome of patients with nonangiosarcoma RA-STS of the chest to determine the outcomes of these patients.…”